Castle Biosciences Inc (CSTL) — Cash Flow-to-Debt Ratio
Castle Biosciences Inc (CSTL) has a Cash Flow-to-Debt Ratio of 0.17x as of June 2026, meaning its operating cash flow of $15.20 Million could theoretically repay 0% of its total liabilities ($91.15 Million) in one year. See Castle Biosciences Inc financial flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Castle Biosciences Inc Cash Flow-to-Debt Ratio (2017–2025)
Historical debt coverage capacity for Castle Biosciences Inc across 9 annual periods. For the full cash flow conversion analysis, see cash flow conversion of Castle Biosciences Inc.
Annual Cash Flow-to-Debt Ratio for Castle Biosciences Inc (2017–2025)
Year-by-year debt coverage analysis for Castle Biosciences Inc. Check Castle Biosciences Inc cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.60x | $64.35 Million | $107.68 Million | ▼ -30.5% |
| 2024 | 0.86x | $64.87 Million | $75.40 Million | ▲ +1049.1% |
| 2023 | -0.09x | $-5.63 Million | $62.07 Million | ▲ +89.5% |
| 2022 | -0.86x | $-41.66 Million | $48.18 Million | ▼ -131.5% |
| 2021 | -0.37x | $-18.98 Million | $50.83 Million | ▼ -189.5% |
| 2020 | 0.42x | $9.87 Million | $23.64 Million | ▲ +106.0% |
| 2019 | 0.20x | $7.01 Million | $34.63 Million | ▲ +153.5% |
| 2018 | -0.38x | $-12.29 Million | $32.47 Million | ▲ +25.4% |
| 2017 | -0.51x | $-12.23 Million | $24.09 Million | — |